Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
VICL's Cash to Debt is ranked higher than
98% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 49.03 vs. VICL: No Debt )
Ranked among companies with meaningful Cash to Debt only.
VICL' s Cash to Debt Range Over the Past 10 Years
Min: 2.33  Med: 45.56 Max: No Debt
Current: No Debt
Equity to Asset 0.93
VICL's Equity to Asset is ranked higher than
91% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. VICL: 0.93 )
Ranked among companies with meaningful Equity to Asset only.
VICL' s Equity to Asset Range Over the Past 10 Years
Min: 0.8  Med: 0.9 Max: 0.94
Current: 0.93
0.8
0.94
Interest Coverage No Debt
VICL's Interest Coverage is ranked higher than
97% of the 464 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. VICL: No Debt )
Ranked among companies with meaningful Interest Coverage only.
VICL' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 6
Z-Score: -4.65
M-Score: -2.59
WACC vs ROIC
12.26%
-74.55%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -32.04
VICL's Operating margin (%) is ranked higher than
60% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -82.26 vs. VICL: -32.04 )
Ranked among companies with meaningful Operating margin (%) only.
VICL' s Operating margin (%) Range Over the Past 10 Years
Min: -730.44  Med: -202.28 Max: -26.06
Current: -32.04
-730.44
-26.06
Net-margin (%) -30.81
VICL's Net-margin (%) is ranked higher than
60% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -80.77 vs. VICL: -30.81 )
Ranked among companies with meaningful Net-margin (%) only.
VICL' s Net-margin (%) Range Over the Past 10 Years
Min: -651.2  Med: -191.08 Max: -24.26
Current: -30.81
-651.2
-24.26
ROE (%) -14.02
VICL's ROE (%) is ranked higher than
64% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. VICL: -14.02 )
Ranked among companies with meaningful ROE (%) only.
VICL' s ROE (%) Range Over the Past 10 Years
Min: -57.41  Med: -33.83 Max: -11.68
Current: -14.02
-57.41
-11.68
ROA (%) -12.73
VICL's ROA (%) is ranked higher than
64% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: -26.97 vs. VICL: -12.73 )
Ranked among companies with meaningful ROA (%) only.
VICL' s ROA (%) Range Over the Past 10 Years
Min: -49.31  Med: -30.49 Max: -10.28
Current: -12.73
-49.31
-10.28
ROC (Joel Greenblatt) (%) -116.30
VICL's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -366.92 vs. VICL: -116.30 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
VICL' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -472.35  Med: -298.96 Max: -113.48
Current: -116.3
-472.35
-113.48
Revenue Growth (3Y)(%) 3.90
VICL's Revenue Growth (3Y)(%) is ranked higher than
51% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. VICL: 3.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
VICL' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -39.7  Med: 1 Max: 27.8
Current: 3.9
-39.7
27.8
EBITDA Growth (3Y)(%) -28.50
VICL's EBITDA Growth (3Y)(%) is ranked lower than
81% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -0.10 vs. VICL: -28.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
VICL' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -56  Med: -1.2 Max: 42.6
Current: -28.5
-56
42.6
EPS Growth (3Y)(%) -28.20
VICL's EPS Growth (3Y)(%) is ranked lower than
78% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. VICL: -28.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
VICL' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -52.4  Med: -4.2 Max: 50.7
Current: -28.2
-52.4
50.7
» VICL's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-29)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

VICL Guru Trades in Q3 2015

Jim Simons 1,169,800 sh (+2.01%)
Murray Stahl 84,500 sh (unchged)
John Rogers 7,436,270 sh (-0.32%)
» More
Q4 2015

VICL Guru Trades in Q4 2015

Jim Simons 1,597,100 sh (+36.53%)
Murray Stahl Sold Out
John Rogers 6,952,175 sh (-6.51%)
» More
Q1 2016

VICL Guru Trades in Q1 2016

Jim Simons 2,073,599 sh (+29.84%)
John Rogers 5,537,755 sh (-20.34%)
» More
Q2 2016

VICL Guru Trades in Q2 2016

Jim Simons 291,909 sh (+40.77%)
John Rogers 528,991 sh (-4.48%)
» More
» Details

Insider Trades

Latest Guru Trades with VICL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:MTNB, AMEX:NBY, NAS:CTRV, OTCPK:CFBFF, AMEX:OGEN, OTCPK:RGRX, NAS:PZRX, NAS:HSGX, NAS:AEZS, NAS:MDGL, OTCPK:ONCYF, AMEX:HEB, OTCPK:EMIS, OTCPK:XBIO, OTCPK:ORGS, NAS:CNAT, NAS:CERC, OTCPK:SPRWF, OTCPK:MNTM, OTCPK:PMCB » details
Traded in other countries:VCC1.Germany,
Vical Inc is engaged in researching and developing biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.

Vical Inc a Delaware corporation, was incorporated in April 1987. The Company researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. It has three active or partnered development programs in the area of infectious disease comprising of an ongoing Phase 3 clinical trial of ASP0113 for prevention of cytomegalovirus, or CMV, reactivation in stem cell transplant recipients and an ongoing Phase 2 clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients, both in collaboration with Astellas Pharma Inc., or Astellas; An ongoing Phase 1/2 clinical trial using our Vaxfectin-formulated therapeutic vaccine for herpes simplex virus type 2, or HSV-2, a cause of recurrent genital herpes; and a completed preclinical program, with an allowed investigational new drug application, or IND, using our CyMVectin prophylactic vaccine formulated with our proprietary Vaxfectin adjuvant to prevent CMV infection before and during pregnancy. The Company has leveraged its patented technologies through licensing and collaboration arrangements, such as its licensing arrangements with Astellas, AnGes MG, Inc., or AnGes, Aqua Health Ltd. of Canada, or Aqua Health, an affiliate of Novartis Animal Health, and Merial Limited, or Merial, a subsidiary of Sanofi, among other biopharmaceutical companies. In addition, it has licensed complementary technologies from research institutions and biopharmaceutical companies. The Company has also granted non-exclusive, academic licenses to its DNA delivery technology patent estate to 11 research institutions including Stanford, Harvard, Yale and the Massachusetts Institute of Technology, or MIT. The Company's key discovery to its patented core DNA delivery technology was that muscle tissues can take up polynucleotide genetic material, such as DNA or RNA, directly, without the use of viral components or other delivery vehicles or technologies, and subsequently express the proteins encoded by the genetic material for periods ranging from weeks to more than a year. Its DNA delivery technology is being developed by the company and its partners in two areas of application, such as Infectious Diseases and Veterinary. The Company is aware of several development-stage and established enterprises, including major pharmaceutical and biotechnology firms, which are engaged in infectious disease vaccine research and development. These include Sanofi, Novartis, GlaxoSmithKline PLC, MedImmune, Inc., a wholly owned subsidiary of AstraZeneca, Merck and Pfizer Inc., among others. Roche, Sanofi, AiCuris GmbH & Co. KG in conjunction with Merck, Chimerix, Inc., and others have products or development programs for CMV treatment and prevention. GlaxoSmithKline plc., Genocea Biosciences, Inc., Agenus, Inc. and others have products or development programs for HSV-2 treatment. New gene-based products for v

Ratios

vs
industry
vs
history
P/B 0.88
VICL's P/B is ranked higher than
93% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. VICL: 0.88 )
Ranked among companies with meaningful P/B only.
VICL' s P/B Range Over the Past 10 Years
Min: 0.61  Med: 2.08 Max: 7.63
Current: 0.88
0.61
7.63
P/S 1.77
VICL's P/S is ranked higher than
87% of the 681 Companies
in the Global Biotechnology industry.

( Industry Median: 11.12 vs. VICL: 1.77 )
Ranked among companies with meaningful P/S only.
VICL' s P/S Range Over the Past 10 Years
Min: 1.33  Med: 11.64 Max: 48.14
Current: 1.77
1.33
48.14
Current Ratio 12.37
VICL's Current Ratio is ranked higher than
82% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.28 vs. VICL: 12.37 )
Ranked among companies with meaningful Current Ratio only.
VICL' s Current Ratio Range Over the Past 10 Years
Min: 3.91  Med: 11.39 Max: 28.07
Current: 12.37
3.91
28.07
Quick Ratio 12.37
VICL's Quick Ratio is ranked higher than
82% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. VICL: 12.37 )
Ranked among companies with meaningful Quick Ratio only.
VICL' s Quick Ratio Range Over the Past 10 Years
Min: 3.91  Med: 11.39 Max: 28.07
Current: 12.37
3.91
28.07
Days Sales Outstanding 84.36
VICL's Days Sales Outstanding is ranked lower than
64% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.43 vs. VICL: 84.36 )
Ranked among companies with meaningful Days Sales Outstanding only.
VICL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.06  Med: 81.34 Max: 217.07
Current: 84.36
38.06
217.07
Days Payable 15.37
VICL's Days Payable is ranked lower than
81% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: 54.75 vs. VICL: 15.37 )
Ranked among companies with meaningful Days Payable only.
VICL' s Days Payable Range Over the Past 10 Years
Min: 7.65  Med: 12.48 Max: 282.72
Current: 15.37
7.65
282.72

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.00
VICL's 3-Year Average Share Buyback Ratio is ranked higher than
84% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. VICL: -2.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
VICL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -24.8  Med: -8.4 Max: -0.2
Current: -2
-24.8
-0.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.24
VICL's Price/Net Cash is ranked higher than
94% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. VICL: 1.24 )
Ranked among companies with meaningful Price/Net Cash only.
VICL' s Price/Net Cash Range Over the Past 10 Years
Min: 0.44  Med: 2.85 Max: 815.79
Current: 1.24
0.44
815.79
Price/Net Current Asset Value 0.98
VICL's Price/Net Current Asset Value is ranked higher than
95% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. VICL: 0.98 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
VICL' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.42  Med: 2.7 Max: 13.78
Current: 0.98
0.42
13.78
Price/Tangible Book 0.88
VICL's Price/Tangible Book is ranked higher than
95% of the 764 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. VICL: 0.88 )
Ranked among companies with meaningful Price/Tangible Book only.
VICL' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.4  Med: 2.21 Max: 13
Current: 0.88
0.4
13
Price/Median PS Value 0.15
VICL's Price/Median PS Value is ranked higher than
95% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. VICL: 0.15 )
Ranked among companies with meaningful Price/Median PS Value only.
VICL' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.15  Med: 1.23 Max: 48.74
Current: 0.15
0.15
48.74
Earnings Yield (Greenblatt) (%) -174.41
VICL's Earnings Yield (Greenblatt) (%) is ranked lower than
94% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. VICL: -174.41 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
VICL' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -266.17  Med: 0.6 Max: 117550
Current: -174.41
-266.17
117550

More Statistics

Revenue (TTM) (Mil) $20.56
EPS (TTM) $ -0.67
Beta1.43
Short Percentage of Float0.29%
52-Week Range $2.81 - 6.17
Shares Outstanding (Mil)9.21

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 18 19 33
EPS ($) -1.02 -0.71 0.13
EPS w/o NRI ($) -1.02 -0.71 0.13
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:VICL

Headlines

Articles On GuruFocus.com
CEOs Sell Vical, PhotoMedex, E.W. Scripps, Smart & Final Stores Jan 18 2016 
Red Hat (RHT) and Five Below (FIVE) Strong Performance Metrics; Vical (VICL) Targets Multi-billion S Mar 26 2015 
John Rogers Comments on Vical Feb 26 2014 
Kids Decide on Dolls or Devices - JAKK, Others 70% Off Sep 17 2013 
Weekly CFO Buys Highlight: VICL, EXA, UCBA, YORW, MGI Jan 21 2013 
Vical Inc. Insiders Boost Shares after Company’s NASDAQ Listing Gets Upgrade Jan 17 2013 
Two Biotech Stocks to Buy, One to Avoid Jan 09 2012 
Vical Inc. (VICL) CEO Vijay B Samant buys 1,000 Shares Jan 20 2011 
Vical Inc. Reports Operating Results (10-Q) Aug 06 2010 
Vical Inc. Reports Operating Results (10-Q) May 07 2010 

More From Other Websites
VICAL INC Financials Aug 19 2016
Vical, Inc. :VICL-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 Aug 11 2016
Vical reports 2Q loss Aug 09 2016
Vical reports 2Q loss Aug 09 2016
Vical Reports Second Quarter 2016 Financial Results Aug 09 2016
VICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 09 2016
Vical Reports Second Quarter 2016 Financial Results Aug 09 2016
Investor Calendar Invites You to the Vical Second Quarter 2016 Earnings Webcast Live on Tuesday,... Aug 08 2016
VICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of... Aug 03 2016
Vical Announces News Release and Conference Call Schedule for Second Quarter 2016 Financial Results Aug 02 2016
Vical Announces News Release and Conference Call Schedule for Second Quarter 2016 Financial Results Aug 02 2016
Vical Announces $7.8 Million Equity Investment by Partner, AnGes MG Aug 01 2016
Vical Announces $7.8 Million Equity Investment by Partner, AnGes MG Aug 01 2016
ETF’s with exposure to Vical, Inc. : July 26, 2016 Jul 26 2016
Vical (VICL) Reports Phase I/II Data on Genital Herpes Vaccine Jun 21 2016
Vical’s Phase 1/2 Trial Data Presented at ASM 2016 Shows Bivalent Vaccine Imparts Reduction in... Jun 20 2016
Vical’s Phase 1/2 Trial Data Presented at ASM 2016 Shows Bivalent Vaccine Imparts Reduction in... Jun 20 2016
Vical to Present HSV-2 Phase 1/2 Data at June ASM Microbe/ICAAC 2016 Conference Jun 13 2016
Vical to Present HSV-2 Phase 1/2 Data at June ASM Microbe/ICAAC 2016 Conference Jun 13 2016
Vical Provides VL-2397 Updates at BIO International Convention May 31 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)